<DOC>
	<DOCNO>NCT02431208</DOCNO>
	<brief_summary>This multicenter , open-label , Phase I study evaluate safety , efficacy , pharmacokinetics atezolizumab alone combination daratumumab and/or various immunomodulatory agent participant MM relapse undergone autologous stem cell transplantation ( ASCT ) . The planned duration study approximately 36 month . Cycle length 21 day Cohorts A C 28 day Cohorts D F .</brief_summary>
	<brief_title>A Study Atezolizumab ( Anti-Programmed Death-Ligand 1 PD-L1 Antibody ) Alone Combination With Immunomodulatory Drug and/or Daratumumab Participants With Multiple Myeloma ( MM )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<criteria>Previous diagnosis MM objective evidence measurable disease Willing able undergo bone marrow aspiration biopsy tissue sample collection Screening study Eastern Cooperative Oncology Group ( ECOG ) performance status score less equal ( &lt; /= ) 2 Left ventricular ejection fraction ( LVEF ) great equal ( &gt; /= ) 40 percent ( % ) Receipt &gt; /=1 3 prior line therapy ( Cohorts A , B , C , D , E ) Receipt &gt; /=3 line prior therapy ( Cohort F ) Absolute neutrophil count ( ANC ) &gt; /=1000 cell per microliter ( cells/mcL ) ( Cohorts A , B , D , E , F ) Transaminase level &lt; /=2.5 time upper limit normal ( ULN ) ( Cohorts A , B , D , E , F ) Platelet count &gt; /=50,000 cells/mcL ( Cohorts A , B , D , E , F ) Total bilirubin &lt; /=2 time ULN ( Cohorts A , B , D , E , F ) Creatinine &lt; /=2.0 milligram per deciliter ( mg/dL ) , creatinine clearance ( CrCl ) use CockcroftGault formula &gt; /=40 milliliter per minute ( mL/min ) 60 mL/min receive lenalidomide ( Cohorts A , B , D , E , F ) Corrected calcium ULN ( Cohorts A , B , D , E , F ) All participant prescribe lenalidomide pomalidomide must counsel minimum every 21 28 day pregnancy precaution risk fetal exposure ( Cohorts B , E , F ) Agree register comply requirement Revlimid Risk Evaluation Mitigation Strategy ( REMS ) program ( Cohorts B E ) Agree register comply requirement Pomalyst REMS program ( Cohort F ) Sufficient recovery first second ASCT within 60 120 day transplant ( Cohort C ) Off antibiotic/antifungal therapy &gt; /=14 day ( Cohort C ) Completion prior radiotherapy ( Cohort C ) Platelet count &gt; /=75,000 cells/mcL ( Cohort C ) ANC &gt; /=1500 cells/mcL ( Cohort C ) Other malignancy within 2 year prior Screening , exception Prior therapy atezolizumab immunotherapy include cluster differentiation ( CD ) 137 agonist , antiprogrammed death ( PD ) 1 , anticytotoxic Tlymphocyte associate protein 4 ( CTLA4 ) , antiPDL1 therapeutic antibody Uncontrolled cancer pain Treatment investigational drug within 30 day 5 halflives investigational drug , whichever long Known hypersensitivity study drug and/or drug class History autoimmune disease except control , treat thyroidism Type 1 diabetes Alkylating agent within 28 day anticancer therapy within 21 day Polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ( POEMS ) syndrome Plasma cell leukemia ( great 2,000 cells/mcL circulate plasma cell standard differential ) Immunosuppressive therapy within 6 week treatment initiation Daily corticosteroid requirement within 2 week treatment initiation Prior allogeneic stem cell transplant solid organ transplant Active hepatitis B , active hepatitis C , human immunodeficiency virus ( HIV ) Uncontrolled , clinically significant pulmonary disease ( example chronic obstructive pulmonary disease , pulmonary hypertension , idiopathic pulmonary fibrosis ) opinion investigator would put participant significant risk pulmonary complication study History pneumonitis Uncontrolled intercurrent illness include limited uncontrolled infection , disseminate intravascular coagulation , psychiatric illness/social situation would limit compliance study requirement Pregnant breastfeed female Inability tolerate thromboprophylaxis ( Cohorts B , E , F ) Evidence progressive MM compare pretransplant evaluation ( Cohort C ) Prior treatment antiCD38 therapy include daratumumab ( Cohorts D , E , F )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>